Reimbursing Designer Drugs
This article was originally published in RPM Report
Now that FDA is pushing a regulatory pathway for personalized medicine through the Critical Path initiative, the next step for industry should be securing payment, especially given what could be relatively high price tags. So what are payors--and the biggest payor of all, CMS--doing to prepare? The answer is, not much.
You may also be interested in...
FDA has granted more than two dozen “Breakthrough Therapy” designations. Not everyone is sure that’s a great thing. Payors, in particular, are getting “nervous” about what hyperfast development of hyper-expensive therapies will mean.
Roche has positioned itself as a leader in the development of more "personalized" health care products. What's needed now, CEO Abercrombie says, is a commitment from FDA to develop consistent approval standards and from CMS to guarantee coverage.
A brief summary of recent clinical developments impacting the medical device industry, including limb regeneration, NIH's research plan for Type I diabetes, heart failure and statins; and new glaucoma research.